Efficacy of imipenem cilastatin injection in patients with pulmonary bacterial infection and its effect on serum PCT and CD64
10.3969/j.issn.1009-0754.2024.10.014
- VernacularTitle:亚胺培南西司他丁注射液在肺部细菌感染患者中的疗效及对血清降钙素原和CD64指数的影响
- Author:
Xianghe LI
1
;
Qing LUO
;
Yueqiong LIU
Author Information
1. 665000 云南普洱,云南省普洱市人民医院
- Keywords:
Imipenem cilastatin injection;
Pulmonary bacterial infection;
Efficacy;
Procalcitonin;
CD64
- From:
Journal of Navy Medicine
2024;45(10):1057-1061
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the efficacy of imipenem cilastatin injection in patients with pulmonary bacterial infection and its effect on serum procalcitonin(PCT)and CD64.Methods A total of 94 patients with pulmonary bacterial infection who were diagnosed and treated in Puer People's Hospital of Yunnan from January 2021 to December 2022 were selected as research objects.The patients were randomly divided into control group and study group(n=47)by random number table method.The control group received cefoperazone-sulbactam sodium,and the study group was given imipenem cilastatin injection.Serum tumor necrosis factor-α(TNF-α),interleukin 6(IL-6),high-sensitivity C reactive protein(hs-CRP),PCT,CD64,clinical efficacy,bacterial clearance and adverse reactions were compared between the two groups.Results TNF-α,IL-6,hs-CRP,PCT and CD64 were decreased after treatment in both groups(P＜0.05),and these indexes in the study group were significantly lower than those in the control group(P＜0.05).The overall clinical response rate of the study group was higher than that of the control group(97.87%vs.80.85%,P＜0.05).The bacterial clearance rate in the study group was higher than that in the control group(89.36%vs.68.09%,P＜0.05).The incidence of adverse reactions in the study group was significantly lower than that in the control group(2.13%vs.14.89%,P＜0.05).Conclusion Imipenem cilastatin can effectively reduce inflammatory reaction and serum PCT and CD64,improve clinical efficacy and bacterial clearance rate,and reduce adverse reactions in patients with pulmonary bacterial infection.
